DUSP6 inhibition overcomes Neuregulin/HER3-driven therapy resistance in HER2+ breast cancer [BT474]
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 3 × BT474, Control, Day 0, vs 3 × BT474, DTP, Day 9, vs 3 × BT474, DTEP, Month 6, vs 3 × BT474, Resistant, Month 9,Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancerEMBO molecular medicine · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE231525_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA966203 and SRA study SRP435623. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7287671 BT474, Control, Day 0, rep1 BT474, Control, Day 0,
- GSM7287672 BT474, Control, Day 0, rep2 BT474, Control, Day 0,
- GSM7287673 BT474, Control, Day 0, rep3 BT474, Control, Day 0,
- GSM7287674 BT474, DTP, Day 9, rep1 BT474, DTP, Day 9,
- GSM7287675 BT474, DTP, Day 9, rep2 BT474, DTP, Day 9,
- GSM7287676 BT474, DTP, Day 9, rep3 BT474, DTP, Day 9,
- GSM7287677 BT474, DTEP, Month 6, rep1 BT474, DTEP, Month 6,
- GSM7287678 BT474, DTEP, Month 6, rep2 BT474, DTEP, Month 6,
- GSM7287679 BT474, DTEP, Month 6, rep3 BT474, DTEP, Month 6,
- GSM7287680 BT474, Resistant, Month 9, rep1 BT474, Resistant, Month…
- GSM7287681 BT474, Resistant, Month 9, rep2 BT474, Resistant, Month…
- GSM7287682 BT474, Resistant, Month 9, rep3 BT474, Resistant, Month…
- GSE231524 DUSP6 inhibition overcomes Neuregulin/HER3-driven therapy resistance in HER2+ breast cancer [MDA] 6 samples shares dusp6, her2, her3-driven, inhibition, neuregulin, resistance, overcomes
- GSE231526 DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer 18 samples shares dusp6, her2, her3-driven, inhibition, neuregulin, overcomes
- GSE190517 DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression (RNA-Seq) 20 samples shares dusp6, inhibition, resistance
- GSE214914 DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression (single-cell RNA-seq) 4 samples shares dusp6, inhibition, resistance
- GSE274142 Single-Cell RNA Sequencing Identifies Molecular Biomarkers Predicting Late Progression to CDK4/6 Inhibition in Patients with HR+/HER2- Metastatic Breast Cancer 89 samples shares her2, inhibition
- GSE300628 HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies 60 samples shares her2, resistance
- GSE274141 Single-Cell RNA Sequencing Identifies Molecular Biomarkers Predicting Late Progression to CDK4/6 Inhibition in Patients with HR+/HER2- Metastatic Breast Cancer [FFPE] 54 samples shares her2, inhibition
- GSE249573 Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies [RNA-seq] 40 samples shares her2, resistance
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.